Evofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Evofem Biosciences (EVFM) Reports Q2 Loss of $1.11
August 2, 2018 7:51 AM EDTEvofem Biosciences (NASDAQ: EVFM) reported Q2 EPS of ($1.11), versus ($0.48) reported last year.
Second Quarter Financial Results and Recent Highlights:
Significant numbers of women completed the 6-month treatment phase of our fully enrolled, confirmatory, Phase 3 clinical trial of Amphora® (L-lactic acid, citric acid, and potassium bitartrate) vaginal gel for the prevention of pregnancy (AMP002). With the study continuing to move ahead of schedule, the Company now expects to report top-line results in late 2018.Received positive early findings from a market... More